Officials from the FDA have approved MiSight 1-day contact lenses (CooperVision), a daily wear, single use contact lens indicated for the use of myopia management. This is the first FDA-approved product clinically proven to slow the progression of myopia, or near-sightedness, when initially prescribed for children ages 8-12 years.
Clinical data has illustrated how digital interventions can have a substantial material benefit on glycemic control in users with diabetes, with 73 of 162 users in the study reducing their average blood glucose levels to under 140 mg/dL.
The study authors wanted to determine the prevalence and clinical significances of red blood cell-bound immunoglobulin G as detected by flow cytometry in polytransfused patients with thalassemia.
Researchers in the JADE MONO-1 study investigated whether patients aged 12 years and older with moderate to severe atopic dermatitis would achieve with abrocitinib could achieve clear or almost clear skin with abrocitinib.
Top news of the day from across the health care landscape.
Jesse C. Dresser, Esq explains the current climate of PBM reform at the NASP Annual Meeting in Washington, DC.
Why is this woman in opioid withdrawal despite high dose methadone administration?
A newly-developed machine learning system may help act as an alert system for potential adverse effects from drug-drug interactions.
Top news of the day from across the health care landscape.
An analysis presented at the American Heart Association Annual Scientific Sessions showed that evolocumab (Repatha, Amgen) lowered the risk of cardiovascular events in patients who have recently had a heart attack.
Officials with the FDA have approved adalimumab-afzb (Abrilada, Pfizer), a biosimilar to Humira, for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.
cvMOBIUS will examine lipid management and the effectiveness of evolocumab (Repatha, Amgen) on cardiovascular outcomes.
Implementing more aggressive treatment plans from the American Heart Association’s 2017 guide were seen as more cost-effective over 10 years.
Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss the goals and importance of his company, Stack, during the NASP Annual Meeting in Washington, DC.
Top news of the week from Specialty Pharmacy Times.
Crizanlizumab-tmca (Adakveo, Novartis) is approved to reduce the frequency of vaso-occlusive crises in patients aged 16 years and older with sickle cell disease.
Top news of the day from across the health care landscape.
Cefiderocol (Fetroja, Shionogi) is indicated for adults with complicated urinary tract infections, including kidney infections caused by Gram-negative pathogens, who have limited or no alternative treatment options.
Cenobamate is an investigational antiepileptic drug that has shown broad spectrum anticonvulsant activity in preclinical studies and seizure models.
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for the treatment of mantle cell lymphoma in adults who have received at least 1 prior therapy.
Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how vertical integration might affect biosimilar availability in specialty pharmacy during the NASP Annual Meeting in Washington, DC.
According to the affiliation agreement, the Institute for Safe Medication Practices will be an ECRI Institute subsidiary when the transaction closes in January, 2020.
In honor of World Diabetes Day, AstraZeneca has launched the campaign Diabetes Can Break Your Heart, the national movement aimed to change the trajectory of heart failure in type 2 diabetes.
Centers for Disease Control and Prevention warns the time for action is now in the "post-antibiotic era."
Receiving a flu shot before a heart bypass surgery can stop inflammation throughout the body and possibly lead to a healthier recovery, according to a preliminary study presented at the American Heart Association’s Scientific Sessions in Philadelphia, Pennsylvania.
The COAST-X study evaluated ixekizumab (Taltz, Eli Lilly) in patients with non-radiographic axial spondyloarthritis.
A study presented at the 2019 ACR/ARP Annual Meeting highlights the need for additional medications for the treatment of juvenile idiopathic arthritis in children.
With vincristine in short supply, Teva will resume production of the chemotherapy agent following its previous decision to remove the product from the market.
The largest study of its kind has found that 40% of the European population carries a genetic variant that leads to antibody resistance against anti-tumor necrosis factor (TNF) drugs, infliximab and adalimumab, and lose response.
Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, was compared with a placebo in patients with ACS and persistent dyslipidemia, in addition to receiving treatment with high-intensity or maximum tolerated statin therapy.
